


FINANCIAL PERFORMANCE

Expenses of the Anticancer Fund and Reliable Cancer Therapies in 2015 **

■ INFORMATION (19.7%)	€ 437,726
■ COMMUNICATION & FUNDRAISING (9.29%)	€ 206,375
■ GENERAL SUPPORT (6.41%)	€ 142,500
■ RESEARCH PROJECTS (54.16%)	€ 1,203,628
■ KNOWLEDGE BUILDING (10.45%)	€ 232,209
TOTAL	€ 2,222,438



ANTICANCER FUND EXPENDITURE for 2015 was € 2,222,438.

Amount spent on

- **INFORMATION:** € 437,726
This expenditure covers two main areas:
 1. website costs, including updating information and adding new information
 2. the costs of maintaining our patient support via info@anticancerfund.org
- **COMMUNICATION AND FUNDRAISING:** € 206,375
This includes a dedicated full-time fundraising employee.
- **GENERAL SUPPORT:** € 142,500
This covers the general administrative support at the Anticancer Fund.
- **RESEARCH PROJECTS:** € 1,203,628
The research projects are managed by our in-house team of scientists and medical doctors in close collaboration with external researchers worldwide.
- **KNOWLEDGE BUILDING:** € 232,209
This covers – amongst others – all investigational costs related to the Hepatocellular Carcinoma project, Aspirin trial in Colorectal cancer and trial in Pancreatic cancer

Total amount spent by the Anticancer Fund: € 2,200,000 well spent in the fight against cancer!

** Anticancer Fund expenses, which covers all project costs of the Swiss, non-profit organization Reliable Cancer Therapies managed by the Anticancer Fund.



Expanding **TREATMENT OPTIONS**
for **CANCER PATIENTS**

ANNUAL IMPACT SHEET 2015

MISSION & VISION

MAIN ACTIVITIES
Research projects
Patient support

NEW IN 2015

FINANCIAL PERFORMANCE



Address Anticancer Fund, Boechoutlaan 221,
1853 Strombeek-Bever, Belgium

Tel. +32 (0)2 268 48 16

Email info@anticancerfund.org

Website www.anticancerfund.org


Support us BE79 5230 8061 2533 - BIC TRIOBEBB



Cancer accounts for 7.4 million deaths per year worldwide. It's the leading cause of deaths around the world.

MAIN ACTIVITIES

1. Research Projects



CLINICAL PROJECTS (total 76.62%)

Nitroglycerine patch & radiotherapy (4.33%)
 Metzolimos (4.95%)
 B-AHEAD 3 (< 1%)
 Artesunate (4.37%)
 Fluvabrex (1.75%)
 Ketorolac (11.41%)
 Ultra low dose chemotherapy (< 1%)
 Vagus Nerve stimulation (5.68%)
 Boost your mind (2.98%)
 Adoptive T-cell therapy (< 1%)
 CUSP9v3 * (2.77%)
 Modulung * (< 1%)
 Glioblastoma newly diagnosed project * (1.09%)
 Pioneer Breast Cancer project * (< 1%)
 Verelst Uterine Fund in collaboration with KU Leuven, Belgium (34.86%)

PRECLINICAL PROJECTS (total 5.38%)

Cryoablation and non-toxic products (< 1%)
 Gloriosa superba extract (1.81%)
 Radiotherapy & Immune Response (2.72%)
 EFFECT - Effectiveness of Endometrial Cancer Treatments in collaboration with the Belgian Cancer Registry (4.14%)
 New project investigations (11.40%)
 Other research projects (2.46%)

Our vision

- The Anticancer Fund is dedicated to expanding the range of treatment options available to patients, regardless of their commercial value.

Our dual mission

- Developing promising cancer treatments that are currently neglected and bringing the most valuable treatments to the patient as quickly as possible.
- Providing free comprehensive, evidence-based information about cancer treatments.











2. Patient Support

In 2015 133 patients received **personalised** information via info@anticancerfund.org.

3. Information via the website

200,372 unique users visited the Anticancer Fund website in 2015. The website contains guides for patients with general information, guides for patients with information per cancer type (ESMO), and information sheets for patients on therapies (mainstream & non-mainstream).

ACF-supported research projects are currently scheduled to include over 640 patients.

 Endometrial cancer: 10 patients	 Colorectal cancer: 10 patients
 Lung cancer: 146 patients	 Liver cancer: 15 patients
 Breast cancer: 469 patients	 Osteosarcoma: 26 patients
 Melanoma: 12 patients	 Glioblastoma: 10 patients
 Optic-pathway glioma: 35 patients	 All cancer types: 56 patients

NEW IN 2015

Projects

	Country	Project area	Budget
CUSP9v3, a combination of 9 repurposed drugs for the treatment of glioblastoma	Germany	GLIOBLASTOMA - phase I / II trial	€ 299,276
Modulung, a combination of 3 repurposed drugs	Germany	NON-SMALL CELL LUNG CANCER - randomized phase II trial	€ 468,999

Publications - ReDO - Repurposing Drugs in Oncology

The Repurposing Drugs in Oncology (ReDO) project is a collaboration with the US not-for-profit organisation Global Cures. The aim of the project is straightforward – to identify a range of existing non-cancer drugs which show strong evidence of anti-cancer activity and which have the potential for clinical use. The value of this concept has been elaborated in an interesting article 'Drug repurposing in oncology – patient and health systems opportunities' in Nature Reviews Clinical Oncology (doi:10.1038/nrclinonc.2015.169).

There is a broad spectrum of drugs that the ReDO project has identified, many of them available as cheap generics, including antibiotics, antifungals and antiparasitics. Taking evidence from a variety of sources, the ReDO project has reviewed, summarized the results and published articles on Clarithromycin (doi:10.3332/ecancer.2015.513), Itraconazole (doi:10.3332/ecancer.2015.521) and Nitroglycerin (doi:10.3332/ecancer.2015.568) in the *ecancermedicinescience*, the open access peer-reviewed cancer journal founded by the European Institute of Oncology. These articles were viewed more than 7,200 times on www.ecancer.org. These publications are part of a continuing collaboration with *ecancer*, the leading oncology channel committed to improving cancer communication and education with the goal of optimizing patient care and outcomes.



Partnership with OvaCure and Van de Velde



After a successful round table conference on 'adoptive TIL transfer-therapy in melanoma and ovarian cancer' in June 2014, a partnership between OvaCure (a Danish non-profit organization focused on the fight against ovarian cancer) and the Anticancer Fund was established. The Anticancer Fund is the scientific strategy partner at OvaCure and member of the OvaCure Scientific and Clinical Advisory Board. (www.ovacure.org)



In June 2015, a partnership between Belgian company Van de Velde nv, one of the market leaders in luxury lingerie, and the Anticancer Fund was formed which will lead to the publication of the breast cancer guide for patients. This guide for patients will explain about the non-conventional treatment options for breast cancer patients and will be available in 2016.

* In preparation

For a detailed list of our projects, contact us or consult our [website](http://www.anticancerfund.org):